Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations

NCT04190628 is registered in ClinicalTrials.gov with ABM Therapeutics Corporation as lead sponsor.

NCT NCT04190628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04190628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Lead sponsor
ABM Therapeutics Corporation
Phase
Phase 1
Overall status
Terminated
Start date
June 16, 2020
Completion date
April 5, 2024
Enrollment
53 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, braf v600 mutation